Acute Coronary Syndrome (ACS) remains a significant cause of morbidity and mortality worldwide. This article provides an overview of recent advancements and best practices in managing this critical condition.
Over the years, significant advancements have been made in the management of ACS. These include the development of high-sensitivity cardiac troponin assays for early diagnosis, and novel antithrombotic therapies such as ticagrelor and prasugrel. The role of non-invasive imaging modalities like coronary computed tomography angiography (CCTA) has also been expanded.
Best practices in ACS management encompass early diagnosis, risk stratification, and individualized treatment. Early invasive strategy is recommended for high-risk patients, while a conservative approach may be suitable for low-risk patients. Dual antiplatelet therapy (DAPT) remains the cornerstone of ACS treatment, with newer agents offering potential benefits.
GDMT plays a crucial role in ACS management. It includes beta-blockers, ACE inhibitors, statins, and antiplatelet agents. Adherence to GDMT is associated with improved outcomes and should be encouraged.
Patients should be educated about the importance of medication adherence, regular follow-up, and lifestyle modifications. These include smoking cessation, regular exercise, a heart-healthy diet, and stress management.
The management of ACS has evolved significantly with advancements in diagnostic tools, pharmacotherapy, and the understanding of disease pathophysiology. Best practices involve a combination of early diagnosis, risk stratification, individualized treatment, GDMT, and patient education. Continued research and innovation are needed to further improve patient outcomes in ACS.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation